지질 나노입자 원료 시장 : 제품, 용도, 적응증, 최종 용도별 - 세계 예측(2024-2032년)

Lipid nanoparticle raw materials market size is estimated to register 5.7% CAGR between 2024 and 2032, driven by expanding applications in pharmaceutical and biotechnology sectors. Lipid nanoparticles (LNPs) have gained significant attention as effective delivery systems for mRNA vaccines. This has led to increased investments and research in this technology for other therapeutic areas, including gene therapy, cancer treatment, and rare diseases.

The rising interest in personalized medicine and precision therapeutics will also influence the market growth. LNPs offer a versatile platform for delivering a wide range of therapeutics with tailored properties, making them ideal for customized treatment regimens. The increasing prevalence of chronic diseases and the need for innovative treatment solutions have spurred research into lipid-based drug delivery systems. As per WHO, chronic diseases cause 41 million deaths annually, accounting for 74% of all global fatalities. The rising government funding and supportive regulatory frameworks are also encouraging innovations and ensuring the availability of high-quality raw materials, adding to the market growth.

The overall industry is classified into product, indication, application, end-use and region.

Based on product, the lipid nanoparticle raw materials market from the reagents segment is predicted to witness substantial growth rate through 2032 due to the synthesis and formulation of lipid nanoparticles. Reagents, such as lipids, solvents, and stabilizers are essential for creating LNPs with precise characteristics to cater to effective drug delivery. The increasing complexity and specificity of LNP formulations for various therapeutic applications, including mRNA vaccines and gene therapies, will also drive the demand for high-quality, reliable reagents.

Lipid nanoparticle raw materials market from the research segment is predicted to record decent growth rate through 2032, owing to the continuous advancements and innovations in nanotechnology and drug delivery systems. Intensive research efforts are focused on optimizing the properties and functionalities of lipid nanoparticles for various therapeutic applications, including targeted drug delivery, gene therapy, and vaccine development.

Asia Pacific lipid nanoparticles raw materials industry size is anticipated to grow at a significant pace over 2024-2032 attributed to the expanding pharmaceutical and biotechnology industries, supported by government investments in healthcare infrastructure and research. The presence of a large pool of skilled researchers and scientists, coupled with cost-effective manufacturing capabilities, is enhancing the development and production of lipid nanoparticle technologies in APAC.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic diseases
    • 3.2.1.2 Advancements in drug delivery technologies
    • 3.2.1.3 Government support and funding
    • 3.2.1.4 Rapid expansion of the biopharmaceutical industry
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory scenario
    • 3.2.2.2 High development costs
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Kits
  • 5.2.1 Ionizable lipids
  • 5.2.2 PEGylated lipids
  • 5.2.3 Sterol lipids
  • 5.2.4 Neutral phospholipids
• 5.3 Reagents
• 5.4 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Therapeutics
• 6.3 Research

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Cancer
• 7.3 Infectious diseases
• 7.4 Blood diseases
• 7.5 Other indications

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Pharmaceutical & biotechnology companies
• 8.3 Academic & research institutes
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Netherlands
  • 9.3.6 Italy
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Biopharma PEG Scientific Inc.
• 10.2 BroadPharm
• 10.3 CordenPharma
• 10.4 Creative Biolabs.
• 10.5 Croda International Plc
• 10.6 Echelon Biosciences
• 10.7 Merck KGaA
• 10.8 NOF Corporation
• 10.9 Polysciences, Inc.
• 10.10 Tebubio